Anavex Leife Sciences +24% Premarket @$6.50; May be Attributed to Report on Australian Alzheimer's Trial

By: via Benzinga
http://www.9news.com.au/national/2016/04/24/19/51/alzheimers-breakthrough-in-melbourne-drug-trial#dfSrjdAC1puZClCF.99
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.